TNF-related Apoptosis-inducing Ligand Delivered by rNDV is a Novel Agent for Cancer Gene Therapy

Technol Cancer Res Treat. 2015 Dec;14(6):737-46. doi: 10.7785/tcrt.2012.500446. Epub 2014 Nov 26.

Abstract

Recombinant Newcastle disease virus (rNDV) as antitumor agent has been shown to be effective for cancer therapy. And TNF-related apoptosis-inducing ligand (TRAIL) also has been demonstrated potentially cancer-therapeutic effects. In this study, we constructed TRAIL delivered by rNDV (rNDV-TRAIL) and investigated whether TRAIL would generate the potential synergistic therapeutic effects with rNDV for cancer therapy. In vitro experiments indicated that TRAIL expressed by rNDV demonstrated good biological activity. TRAIL significantly enhanced inducing apoptosis of rNDV in death receptor expression cancer cell lines. Experiments in malignant melanoma-bearing mice demonstrated that expression of TRAIL delivered by rNDV significantly inhibited the tumor growth and prolonged the survival of treated animals compared to control. In conclusion, oncolytic capacity of rNDV was augmented by TRAIL and the inherent anti-neoplastic properties of NDV were enhanced by the introduction of therapeutic TRAIL gene.

Keywords: Antitumor drug; Cancer gene therapy; Cancer therapy; Recombinant Newcastle disease virus; TNF-related apoptosis-inducing ligand.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay
  • Genetic Therapy / methods*
  • Genetic Vectors
  • Humans
  • Melanoma, Experimental / therapy*
  • Mice
  • Mice, Inbred C57BL
  • Newcastle disease virus
  • Polymerase Chain Reaction
  • TNF-Related Apoptosis-Inducing Ligand / administration & dosage*
  • Xenograft Model Antitumor Assays

Substances

  • TNF-Related Apoptosis-Inducing Ligand